NAS
JANX icon

Nykredit A/S’s Janux Therapeutics JANX Stock Holding History

Nykredit A/S’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91K Buy
+124
New +$1.8K ﹤0.01% 1936

Other funds holding JANX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's JANX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Janux Therapeutics (JANX) in Q2 2026: 124 shares worth $1.91K. The stake represents ﹤0.01% of the portfolio and ranks #1936 among its holdings.

121 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Nykredit A/S held 124 shares of Janux Therapeutics worth $1.91K as of Q2 2026.
  • Janux Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1936 holding.
  • 121 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.